Large-dose infusions of heparinoid ORG 10172 in ischemic stroke

E. W. Massey; J. Biller; J. N. Davis; H. P. Adams; J. R. Marler; L. B. Goldstein; M. Alberts; A. Bruno

doi:10.1161/01.STR.21.9.1289

Large-dose infusions of heparinoid ORG 10172 in ischemic stroke

E. W. Massey, J. Biller, J. N. Davis, H. P. Adams, J. R. Marler, L. B. Goldstein, M. Alberts, A. Bruno

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

We evaluated the safety and possible efficacy of large doses of the heparinoid ORG 10172 in 57 patients with acute or progressing ischemic stroke. Patients received a loading bolus of the drug followed by a maintenance intravenous infusion for 7 days. The plasma level of ORG 10172 was monitored by the degree of inhibition of coagulation factor Xa. In general, the drug was well tolerated and few hemorrhagic complications occurred. Two patients with large cardioembolic hemispheric strokes had intracranial hemorrhagic complications. Most patients improved during treatment. By 3 months after the stroke, 37 patients (65%) had a favorable outcome (minimal or no residual disability). This study suggests that high-dose intravenous infusions of ORG 10172 can be safely given to patients with acute ischemic stroke.

Original language	English (US)
Pages (from-to)	1289-1292
Number of pages	4
Journal	Stroke
Volume	21
Issue number	9
DOIs	https://doi.org/10.1161/01.STR.21.9.1289
State	Published - Sep 1990

Keywords

Anticoagulants
Cerebral ischemia
Early treatment

ASJC Scopus subject areas

Clinical Neurology
Cardiology and Cardiovascular Medicine
Advanced and Specialized Nursing

Access to Document

10.1161/01.STR.21.9.1289

Fingerprint Dive into the research topics of 'Large-dose infusions of heparinoid ORG 10172 in ischemic stroke'. Together they form a unique fingerprint.

Cite this

@article{86462b76cdce4e2aa123fe9695577914,

title = "Large-dose infusions of heparinoid ORG 10172 in ischemic stroke",

abstract = "We evaluated the safety and possible efficacy of large doses of the heparinoid ORG 10172 in 57 patients with acute or progressing ischemic stroke. Patients received a loading bolus of the drug followed by a maintenance intravenous infusion for 7 days. The plasma level of ORG 10172 was monitored by the degree of inhibition of coagulation factor Xa. In general, the drug was well tolerated and few hemorrhagic complications occurred. Two patients with large cardioembolic hemispheric strokes had intracranial hemorrhagic complications. Most patients improved during treatment. By 3 months after the stroke, 37 patients (65%) had a favorable outcome (minimal or no residual disability). This study suggests that high-dose intravenous infusions of ORG 10172 can be safely given to patients with acute ischemic stroke.",

keywords = "Anticoagulants, Cerebral ischemia, Early treatment",

author = "Massey, {E. W.} and J. Biller and Davis, {J. N.} and Adams, {H. P.} and Marler, {J. R.} and Goldstein, {L. B.} and M. Alberts and A. Bruno",

year = "1990",

month = sep,

doi = "10.1161/01.STR.21.9.1289",

language = "English (US)",

volume = "21",

pages = "1289--1292",

journal = "Stroke",

issn = "0039-2499",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Large-dose infusions of heparinoid ORG 10172 in ischemic stroke

AU - Massey, E. W.

AU - Biller, J.

AU - Davis, J. N.

AU - Adams, H. P.

AU - Marler, J. R.

AU - Goldstein, L. B.

AU - Alberts, M.

AU - Bruno, A.

PY - 1990/9

Y1 - 1990/9

N2 - We evaluated the safety and possible efficacy of large doses of the heparinoid ORG 10172 in 57 patients with acute or progressing ischemic stroke. Patients received a loading bolus of the drug followed by a maintenance intravenous infusion for 7 days. The plasma level of ORG 10172 was monitored by the degree of inhibition of coagulation factor Xa. In general, the drug was well tolerated and few hemorrhagic complications occurred. Two patients with large cardioembolic hemispheric strokes had intracranial hemorrhagic complications. Most patients improved during treatment. By 3 months after the stroke, 37 patients (65%) had a favorable outcome (minimal or no residual disability). This study suggests that high-dose intravenous infusions of ORG 10172 can be safely given to patients with acute ischemic stroke.

AB - We evaluated the safety and possible efficacy of large doses of the heparinoid ORG 10172 in 57 patients with acute or progressing ischemic stroke. Patients received a loading bolus of the drug followed by a maintenance intravenous infusion for 7 days. The plasma level of ORG 10172 was monitored by the degree of inhibition of coagulation factor Xa. In general, the drug was well tolerated and few hemorrhagic complications occurred. Two patients with large cardioembolic hemispheric strokes had intracranial hemorrhagic complications. Most patients improved during treatment. By 3 months after the stroke, 37 patients (65%) had a favorable outcome (minimal or no residual disability). This study suggests that high-dose intravenous infusions of ORG 10172 can be safely given to patients with acute ischemic stroke.

KW - Anticoagulants

KW - Cerebral ischemia

KW - Early treatment

UR - http://www.scopus.com/inward/record.url?scp=0025183006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025183006&partnerID=8YFLogxK

U2 - 10.1161/01.STR.21.9.1289

DO - 10.1161/01.STR.21.9.1289

M3 - Article

C2 - 2396265

AN - SCOPUS:0025183006

VL - 21

SP - 1289

EP - 1292

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -